



Review

The anti-apoptotic actions of nitric oxide in hepatocytes

Jianrong Li¹ and Timothy R Billiar^{*1}

¹ Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA

* corresponding author: Timothy R Billiar, M.D., Watson Professor of Surgery, A1010 Presbyterian University Hospital, Pittsburgh, PA 15213, USA
tel: 412/648-9862; fax: 412/648-1033;
e-mail: billiartr@msx.upmc.edu

Received 11.5.99; accepted 21.7.99

Edited by P Nicotera

Abstract

Nitric oxide (NO) has anti-apoptotic actions in hepatocytes *in vitro* and *in vivo*. The protection is mediated via the S-nitrosylation of procaspases as well as the active caspase enzymes. NO stimulation of the cGMP/protein kinase G pathway also appears to contribute to the protective effect of NO. Here we review the evidence for the direct inhibition of NO with the apoptotic signaling pathways in hepatocytes.

Keywords: caspases; S-nitrosylation; apoptosis; inducible NO synthase

Abbreviations: ActD, actinomycin D; NO, nitric oxide; NOS, nitric oxide synthase; iNOS, inducible nitric oxide synthase; TNF α , tumor necrosis factor α ; TGF β , transforming growth factor β ; NIL, L-N^G-iminoethyl-lysine; DTT, dithiothreitol

It is well established that liver produces either small amounts of nitric oxide (NO) constitutively or large amounts of NO under a number of inflammatory conditions.¹ Both parenchymal and nonparenchymal liver cells have been shown to generate NO. Hepatocytes constitute the majority cells of the liver (over 70%) and play important roles in metabolism, detoxification and production of plasma proteins. In the absence of exogenous stimulation hepatocytes probably produce little if any NO. However, following exposure to cytokines such as interleukin 1 or tumor necrosis factor alpha (TNF α), hepatocytes express the inducible NO synthase (iNOS) and produce high levels of NO for prolonged periods. Other stimuli such as bacterial lipopolysaccharide, interferon gamma and redox stress can also augment hepatocyte iNOS expression. The low levels of NO produced by constitutive endothelial NO synthase (eNOS) maintain hepatic perfusion and protect the liver under inflammatory conditions. The higher amounts of NO produced by iNOS participate in immune-defense against invading pathogens. However, recent studies indicate that the inducible NO production also plays important roles in modulating hepatocellular cell death

and tissue injury. Depending on the type and extent of insults, iNOS expression can either protect the liver from damage or promote hepatocellular injury. For example, we^{2,3} and others⁴ have shown that pharmacological doses of NO donor conferred protection against TNF α -induced liver injury in D-galactosamine-sensitized animals and that administration of iNOS inhibitors resulted in increased apoptosis in the liver of animals treated with endotoxin.² Similarly, iNOS expression limited hepatocyte apoptosis during liver regeneration.⁵ In contrast, iNOS expression in response to hemorrhagic shock actually promoted liver damage.⁶ We have postulated that one of the determinants of iNOS toxicity in liver is the degree of associated redox stress.⁷

The potent anti-apoptotic properties of NO in hepatocytes have now been established in *in vitro* and *in vivo* studies. Hepatocytes are rather resistant to NO-mediated toxicity. Millimolar concentrations of NO donors, much higher than levels known to induce apoptotic cell death in many other cell types,⁸ actually cause hepatocyte necrosis but not apoptosis (unpublished observations). However, cultured hepatocytes readily undergo apoptotic cell death upon exposure to Fas ligand, TNF α plus the transcriptional inhibitor actinomycin D, transforming growth factor β (TGF β) or growth factor depletion.^{9–13} We have found that NO suppresses not only Fas- or TNF α -mediated apoptosis, but also non-receptor-mediated apoptosis such as spontaneous and hydrogen peroxide-induced apoptotic cell death in hepatocytes.^{10,14} Both the exogenously provided NO via various NO donors and endogenous NO derived from induction of iNOS with cytokines prevented hepatic apoptosis.¹⁰ Adenoviral gene transfer of human iNOS into hepatocytes also effectively inhibited TNF α +ActD-induced apoptosis, a response completely reversed by blocking NO generation with iNOS inhibitor L-N^G-iminoethyl-lysine (NIL).^{15,16} Moreover, NO exhibits a similar potency for suppressing apoptosis in the liver *in vivo*. Using a NO donor that concentrates NO release in hepatocytes, we have shown that NO almost completely prevented the massive and rapid apoptotic liver destruction induced by the administration of TNF α and D-galactosamine.²

Our laboratory has begun to examine the mechanism by which NO inhibits hepatic apoptosis with a focus on how NO interacts with the apoptotic signaling cascade in hepatocytes. Initial studies examined the effect of NO pretreatment on hepatocyte susceptibility to TNF α -induced cell death. We found that pretreatment with a NO donor or pre-induction of iNOS stimulated the expression of the inducible heat shock protein 70 (Hsp70) in hepatocytes and inhibited subsequent TNF α +ActD-induced hepatocyte apoptosis.¹⁷ The protective effect of NO pretreatment on TNF α +ActD-induced apoptosis correlated with the expression level of Hsp70, and this protection was lost when

Hsp70 expression was blocked with antisense oligonucleotides. Although Hsp70 has also been shown to suppress apoptosis in a number of other cell systems, how Hsp70 prevents cells from TNF α -mediated cell death remains unknown. Recent evidence suggests that Hsp70 acts downstream of caspase activation in tumor cell lines.¹⁸ In addition, NO also induces heme oxygenase-1 expression in hepatocytes, and this enzyme produces the potent antioxidant biliverdin to prevent H₂O₂-induced toxicity.¹⁴

Simultaneous exposure to NO donor not only suppressed TNF α -induced apoptosis but also Fas and nutrient deprivation-induced apoptosis.^{10,16} These findings suggested a direct interaction between NO and the apoptotic signaling cascade. Based on this observation we assessed the effects of NO on caspase activity and activation. Several of the 14 identified mammalian caspases are known to participate in apoptotic signaling.¹⁹ These enzymes exist in cells as zymogens and require proteolytic cleavage into the enzymatically active form. Initiator caspases, such as caspase-8, can propagate the apoptotic signal by activating downstream effector caspases, such as caspase-3, which serve as executioners in the terminal phase of apoptosis by cleaving key death substrates (such as PARP, DNA-dependent kinase, and the inhibitor of the caspase-activated deoxyribonuclease). Activated upstream caspases can also cleave certain Bcl2 family members, leading to the release of cytochrome *c* from mitochondria. Released cytochrome *c* then forms a complex with apoptotic protease activating factor 1 (Apaf-1), dATP and procaspase-9, resulting in activation of procaspase-9 that in turn activates procaspase-3. Growing evidence has demonstrated the essential involvement of caspase-3-like proteases, but not caspase-1, in hepatocyte apoptosis induced by TNF α , Fas, TGF β , ischemia/reperfusion and toxic bile salts.^{10,16,20–26} We have confirmed that caspase activation takes place in hepatocytes stimulated to undergo apoptosis.^{10,16} Numerous caspases are activated in hepatocytes and pan-caspase inhibitors and inhibitor more specific for caspase-3-like proteases prevent hepatocyte apoptosis.¹⁶ Hepatocytes exposed to NO via donors or through the expression of iNOS display much lower levels of caspase activity coinciding with enhanced cell survival.^{10,16} Similar observations take place *in vivo* in TNF α and D-galactosamine treated rats infused with a liver selective NO donor.³ Under all circumstances caspase-3-like activity could be increased if lysates from the cells or whole liver were treated with the strong reducing agent dithiothreitol (DTT),¹⁰ implicating S-nitrosylation as a mechanism for the NO-dependent inhibition of caspase activity and hence protection from cell death.^{22,27–31} This is consistent with similar observations made in endothelial cells,²⁷ neurons,²⁸ eosinophils,³² lymphocytes^{33,34} and several tumor cell lines.³⁵ Indeed, when seven recombinant active caspases were exposed to NO, they were all inhibited by NO in a manner reversible by DTT.²²

Besides direct inactivation of active caspases through S-nitrosylation, NO also inhibits the activation process of procaspases. To determine if NO prevents the proteolytic processing of procaspases we first identified the total number of caspases activated in apoptotic hepatocytes. Affinity labeling of caspases activated in TNF α +ActD-

treated hepatocytes with biotin-tagged the pan-caspase inhibitor VAD-fmk revealed that at least four different active caspase species were present in hepatocytes undergoing apoptosis.¹⁶ NO blocked the detection and appearance of all four active caspase species. Western blotting analysis for the detection of the proteolytic fragment of caspases confirmed that NO treatment prevented the proteolytic processing of both procaspase-3 and -8.¹⁶ These findings support the idea that NO can act at the earliest steps of the apoptosis signal cascade by blocking the apical procaspase-8 proteolytic activation. This is consistent with the observation that NO inhibits Bcl2 cleavage, cytochrome *c* release, loss of mitochondrial transmembrane potential and activation of caspase-3, all events distal to the proteolytic activation of caspase-8.^{16,36}

Although it is currently unknown whether NO has any effect on the assembling and recruitment of procaspase-8 to the TNF α -receptor 1 (death signaling complex), the fact that NO directly S-nitrosylates caspase-8 and inhibits caspase-8 activity *in vitro* suggests that a plausible mechanism is the S-nitrosylation of procaspase-8.²² This could prevent autoactivation of procaspase-8 that is thought to occur when the zymogen is bound to FADD. However, this proposed mechanism poses a significant problem. If NO inhibits apoptosis by blocking caspase processing and catalytic activity, how is it that NO initiates caspase-dependent apoptosis in some cell types (see parallel review by Brune in this issue).³⁷ The answer is probably that cells differ in their capacity to carry out S-nitrosylation reactions. The efficiency of S-nitrosylation in cells is dependent on the chemical fate of NO in a particular environment. For NO to nitrosylate a target, it must first give up one electron to form NO⁺ or its equivalent. Potential electron acceptors include oxygen molecule and transition metals such as iron (also see the review by Lipton in this issue).³⁸ The abundant iron content in hepatocytes may explain the efficiency of S-nitrosylation of protein targets including caspases in these cells. We have found that it is necessary to pretreat MCF-7 cells³⁶ and RAW264.7 cells with iron to observe NO-dependent inhibition of caspase activity and prevention of apoptosis. Other pathways to S-nitrosylation undoubtedly exist and it is likely that the redox status of a cell will determine the capacity of NO to either protect or injure a cell. This is supported by data indicating that iNOS expression, typically well tolerated by hepatocytes, becomes injurious in states of severe redox stress such as ischemia/reperfusion or hemorrhagic shock.⁶ The finding that endogenous NO nitrosylates endogenous caspase-3 in intact cells reinforced the concept that NO suppresses apoptosis via inhibiting caspases through S-nitrosylation.^{39,40}

NO-mediated protection against apoptosis in some cell types, such as motor and sympathetic neurons^{41,42} and splenocytes,⁴³ occurs via a cGMP-dependent mechanism. Hepatocytes are also partially protected by cyclic nucleotides¹⁰ (and unpublished data), and NO has been previously shown to increase cGMP levels in hepatocytes.⁴⁴ NO-mediated inhibition of apoptotic cell death in cultured hepatocytes can be partially mimicked with a cGMP analog.¹⁰ In fact, 8-Br-cGMP at concentration of




Figure 1 The proposed sites for NO in the inhibition of TNF α +ActD-induced apoptosis in hepatocytes

800 μ M blocks the proteolytic activation of caspase-3, the release of cytochrome *c*, and the loss of mitochondrial transmembrane potential in cells challenged with TNF α and ActD (unpublished data). This cGMP effect appears to be mediated through the activation of protein kinase G, but may also depend on the activation of protein kinase A. Inhibition of soluble guanylyl cyclase with ODC, partially prevented the anti-apoptotic effect of NO,¹⁰ suggesting that the protective actions of NO in hepatocytes are mediated in part via cGMP. The mechanism by which cGMP suppresses caspase activation is not clear, but probably involves the interaction of the cGMP-dependent protein kinase pathway with the apoptotic signaling pathway.

In summary, the dominant protective action of NO in hepatocytes appears to be direct inhibition of caspases through S-nitrosylation with cGMP playing a minor role. Nonetheless, the dual mechanisms for protection by NO are unique to hepatocytes and the proposed sites for NO-mediated inhibition of apoptotic signaling in hepatocytes are depicted in Figure 1. As our understanding of the mechanisms by which NO inhibits apoptosis in hepatocytes advances and methods to deliver NO to liver improve, it may be possible to devise therapies to limit hepatic injury.

Acknowledgements

The research described in this review was supported by National Institutes of Health grants GM-44100 and GM-37753. J Li is supported by a postdoctoral fellowship from National Research Service Award GM19866.

References

1. Taylor BS, Alarcon LH and Billiar TR (1998) Inducible nitric oxide synthase in the liver: regulation and function. *Biochemistry (Mosc.)* 63: 766–781
2. Ou J, Carlos TM, Watkins SC, Saavedra JE, Keefer LK, Kim YM, Harbrecht BG and Billiar TR (1997) Differential effects of nonselective nitric oxide synthase (NOS) and selective inducible NOS inhibition on hepatic necrosis, apoptosis, ICAM-1 expression, and neutrophil accumulation during endotoxemia. *Nitric Oxide* 1: 404–416
3. Saavedra JE, Billiar TR, Williams DL, Kim YM, Watkins SC and Keefer LK (1997) Targeting nitric oxide (NO) delivery in vivo. Design of a liver-selective NO donor prodrug that blocks tumor necrosis factor- α -induced apoptosis and toxicity in the liver. *J. Med. Chem.* 40: 1947–1954
4. Böhlinger I, Leist M, Barsig J, Uhlig S, Tiegs G and Wendel A (1995) Interleukin-1 and nitric oxide protect against tumor necrosis factor- α -induced liver injury through distinct pathways. *Hepatology* 22: 1829–1837
5. Rai RM, Lee FY, Rosen A, Yang SQ, Lin HZ, Koteish A, Liew FY, Zaragoza C, Lowenstein C and Diehl AM (1998) Impaired liver regeneration in inducible nitric oxide synthase deficient mice. *Proc. Natl. Acad. Sci. USA* 95: 13829–13834
6. Hierholzer C, Harbrecht B, Menezes JM, Kane J, MacMicking J, Nathan CF, Peitzman AB, Billiar TR and Tweardy DJ (1998) Essential role of induced nitric oxide in the initiation of the inflammatory response after hemorrhagic shock. *J. Exp. Med.* 187: 917–928
7. Li J and Billiar TR (1999) Determinants of nitric oxide protection and toxicity in liver. *Am. J. Physiol.* 276: G1069–1073
8. Kim YM, Bombeck CA and Billiar TR (1997) Nitric oxide as a bifunctional regulator of apoptosis. *Circ. Res.* 84: 253–256
9. Leist M, Gantner F, Böhlinger I, Tiegs G, Germann PG and Wendel A (1995) Tumor necrosis factor-induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. *Am. J. Pathol.* 146: 1220–1234
10. Kim YM, Talanian RV and Billiar TR (1997) Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. *J. Biol. Chem.* 272: 31138–31148

11. Oberhammer FA, Pavelka M, Sharma S, Tiefenbacher R, Purchio AF, Bursch W and Schulte-Hermann R (1992) Induction of apoptosis in cultured hepatocytes in regressing liver by transforming growth factor beta 1. *Proc. Natl. Acad. Sci. USA* 89: 5408–5412
12. Ni R, Tomita Y, Matsuda K, Ichihara A, Ishimura K, Ogasawara J and Nagata S (1994) Fas-mediated apoptosis in primary cultured mouse hepatocytes. *Exp. Cell Res.* 215: 332–337
13. Leist M, Gantner F, Böhlinger I, Germann PG, Tiegs G and Wendel A (1994) Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-alpha requires transcriptional arrest. *J. Immunol.* 153: 1778–1788
14. Kim YM, Bergonia H and Lancaster Jr JR (1995) Nitrogen oxide-induced autoprotection in isolated rat hepatocytes. *FEBS Lett.* 374: 228–232
15. Tzeng E, Billiar TR, Williams DL, Li J, Lizonova A, Kovesdi I and Kim YM (1998) Adenovirus-mediated inducible nitric oxide synthase gene transfer inhibits hepatocyte apoptosis. *Surgery* 124: 278–283
16. Li J, Bombeck CA, Yang S, Kim YM and Billiar TR (1999) Nitric oxide suppresses apoptosis via interrupting caspase activation and mitochondrial dysfunction in cultured hepatocytes. *J. Biol. Chem.* 274: 17325–17333
17. Kim YM, de Vera ME, Watkins SC and Billiar TR (1997) Nitric oxide protects cultured rat hepatocytes from tumor necrosis factor-alpha-induced apoptosis by inducing heat shock protein 70 expression. *J. Biol. Chem.* 272: 1402–1411
18. Jaattela M, Wissing D, Kokholm K, Kallunki T and Egeblad M (1998) Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases. *EMBO J.* 17: 6124–6134
19. Thornberry NA and Lazebnik Y (1998) Caspases: enemies within. *Science* 281: 1312–1316
20. Jones RA, Johnson VL, Buck NR, Dobrota M, Hinton RH, Chow SC and Kass GE (1998) Fas-mediated apoptosis in mouse hepatocytes involves the processing and activation of caspases. *Hepatology* 27: 1632–1642
21. Inayat-Hussain SH, Couet C, Cohen GM and Cain K (1997) Processing/activation of CPP32-like proteases is involved in transforming growth factor beta1-induced apoptosis in rat hepatocytes. *Hepatology* 25: 1516–1526
22. Li J, Billiar TR, Talanian RV and Kim YM (1997) Nitric oxide inhibits seven members of the caspase family via S-nitrosylation. *Biochem. Biophys. Res. Commun.* 240: 419–424
23. Cain K, Inayat-Hussain SH, Couet C and Cohen GM (1996) A cleavage-site-directed inhibitor of interleukin-1 beta-converting enzyme-like proteases inhibits apoptosis in primary cultures of rat hepatocytes. *Biochem. J.* 314: 27–32
24. Cursio R, Gugenheim J, Ricci JE, Crenesse D, Rostagno P, Maulon L, Saint-Paul MC, Ferrua B and Auberger AP (1999) A caspase inhibitor fully protects rats against lethal normothermic liver ischemia by inhibition of liver apoptosis. *FASEB J.* 13: 253–261
25. Rodriguez I, Matsuura K, Ody C, Nagata S and Vassalli P (1996) Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death. *J. Exp. Med.* 184: 2067–2072
26. Faubion WA, Guicciardi ME, Miyoshi H, Bronk SF, Roberts PJ, Svingen PA, Kaufmann SH and Gores GJ (1999) Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. *J. Clin. Invest.* 103: 137–145
27. Dimmeler S, Haendeler J, Nehls M and Zeiher AM (1997) Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. *J. Exp. Med.* 185: 601–617
28. Tennesi L, D'Emilia DM and Lipton SA (1997) Suppression of neuronal apoptosis by S-nitrosylation of caspases. *Neurosci. Lett.* 236: 139–142
29. Melino G, Bernassola F, Knight RA, Corasaniti MT, Nistico G and Finazzi-Agro A (1997) S-nitrosylation regulates apoptosis. *Nature* 388: 432–433
30. Mohr S, Zech B, Lapetina EG and Brune B (1997) Inhibition of caspase-3 by S-nitrosation and oxidation caused by nitric oxide. *Biochem. Biophys. Res. Commun.* 238: 387–391
31. Ogura T, Tatemichi M, Esumi H (1997) Nitric oxide inhibits CPP32-like activity under redox regulation. *Biochem. Biophys. Res. Commun.* 236: 365–369
32. Beauvais F, Michel L and Dubertret L (1995) The nitric oxide donors, azide and hydroxylamine, inhibit the programmed cell death of cytokine-deprived human eosinophils. *FEBS Lett.* 361: 229–232
33. Mannick JB, Asano K, Izumi K, Kieff E and Stamler JS (1994) Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. *Cell* 79: 1137–1146
34. Sciorati C, Rovere P, Ferrarini M, Heltai S, Manfredi AA and Clementi E (1997) Autocrine nitric oxide modulates CD95-induced apoptosis in gammadelta T lymphocytes. *J. Biol. Chem.* 272: 23211–23215
35. Mannick JB, Miao XQ and Stamler JS (1997) Nitric oxide inhibits Fas-induced apoptosis. *J. Biol. Chem.* 272: 24125–24128
36. Kim YM, Kim TH, Seol DW, Talanian RV and Billiar TR (1998) Nitric oxide suppression of apoptosis occurs in association with an inhibition of Bcl-2 cleavage and cytochrome c release. *J. Biol. Chem.* 273: 31437–34441
37. Brüne B, Knethen A and Sandau KB (1999) Nitric oxide (NO): an effector of apoptosis. *Cell Death Diff.* in press.
38. Lipton SA (1999) Neuronal protection and destruction. *Cell Death Diff.* in press.
39. Mannick JB, Hausladen A, Liu L, Hess DT, Zeng M, Miao QX, Kane LS, Gow AJ and Stamler JS (1999) Fas-Induced Caspase Denitrosylation. *Science* 284: 651–654
40. Rossig L, Fichtlscherer B, Breitschopf K, Haendeler J, Zeiher AM, Misch A and Dimmeler S (1999) Nitric oxide inhibits caspase-3 by S-nitrosation in vivo. *J. Biol. Chem.* 274: 6823–6826
41. Estevez AG, Spear N, Thompson JA, Cornwell TL, Radi R, Barbeito L and Beckman JS (1998) Nitric oxide-dependent production of cGMP supports the survival of rat embryonic motor neurons cultured with brain-derived neurotrophic factor. *J. Neurosci.* 18: 3708–3714
42. Farinelli SE, Park DS and Greene LA (1996) Nitric oxide delays the death of trophic factor-deprived PC12 cells and sympathetic neurons by a cGMP-mediated mechanism. *J. Neurosci.* 16: 2325–2334
43. Genaro AM, Hortelano S, Alvarez A, Martinez C and Bosca L (1995) Splenic B lymphocyte programmed cell death is prevented by nitric oxide release through mechanisms involving sustained Bcl-2 levels. *J. Clin. Invest.* 95: 1884–1890
44. Billiar TR, Curran RD, Harbrecht BG, Stadler J, Williams DL, Ochoa JB, Di Silvio M, Simmons RL and Murray SA (1992) Association between synthesis and release of cGMP and nitric oxide biosynthesis by hepatocytes. *Am. J. Physiol.* 262: C1077–1082